Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

MLA

Thomas, Xavier, et al. “Comparison of High-Dose Cytarabine and Timed-Sequential Chemotherapy as Consolidation for Younger Adults with AML in First Remission: The ALFA-9802 Study.” Blood, vol. 118, no. 7, Aug. 2011, pp. 1754–62. EBSCOhost, https://doi.org/10.1182/blood-2011-04-349258.

APA

Thomas, X., Elhamri, M., Raffoux, E., Renneville, A., Pautas, C., de Botton, S., de Revel, T., Reman, O., Terré, C., Gardin, C., Chelghoum, Y., Boissel, N., Quesnel, B., Hicheri, Y., Bourhis, J.-H., Fenaux, P., Preudhomme, C., Michallet, M., Castaigne, S., & Dombret, H. (2011). Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 118(7), 1754–1762. https://doi.org/10.1182/blood-2011-04-349258

Chicago

Thomas, Xavier, Mohamed Elhamri, Emmanuel Raffoux, Aline Renneville, Cécile Pautas, Stéphane de Botton, Thierry de Revel, et al. 2011. “Comparison of High-Dose Cytarabine and Timed-Sequential Chemotherapy as Consolidation for Younger Adults with AML in First Remission: The ALFA-9802 Study.” Blood 118 (7): 1754–62. doi:10.1182/blood-2011-04-349258.